End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.69 CNY | +2.11% | +6.33% | -2.11% |
04-25 | Hubei Dinglong CO.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | Nomura Adjusts Hubei Dinglong’s Price Target to 24 Yuan From 22 Yuan, Keeps at Buy | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.09 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.11% | 3.07B | - | ||
+14.70% | 64.97B | A- | ||
-1.61% | 47.76B | A- | ||
+14.58% | 40.72B | B+ | ||
+20.84% | 26.88B | A- | ||
+9.54% | 19.29B | C+ | ||
+1.16% | 17.53B | B+ | ||
-21.87% | 16.03B | A- | ||
+1.11% | 15.17B | B+ | ||
-11.34% | 15.06B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300054 Stock
- Ratings Hubei Dinglong CO.,Ltd.